Tempus Inc’s revenue leap of 82.9% year-on-year was largely driven by Genomics (laboratory services). The company realised 76.4% of its revenue or $435.6 million from Genomics in the first half of 2025 compared to 68.9% of revenue or $214.9 million in the corresponding period of the previous year. On the other hand, the proportion of revenue made from data and services dropped from 31.1% to 23.6%. Â
The gross profit more than doubled between the first half of 2024 and the first half of 2025. TEMPUS AI posted a gross profit of $350.2 million for the six months to 30th June 2025 as against $153.2 million for the first six months of 2024. The company declared a net loss of $110.9 million in half year 2024 compared to $617 million net loss posted a year ago.Â
| Â | Jan-Jun 2025Â | Jan-Jun 2024Â | % Change |
| Turnover | $570,372,000 | $311,789,000 | 82.9% |
| Profit Before Tax | -$152,865,000 | -$616,849,000 | -75.2% |
| Profit After Tax | -$110,880,000 | -$616,955,000 | -82.0% |
- Gross profit margin is rising
The gross profit margin increased from 49.1% to 61.4%Â as revenue rose faster than cost of revenues. Cost of revenues increased by 38.8% from $158.6 million in 2024 half year to $220.1 million in the first 6 months of 2025.Â
- The losses are decreasing
TEMPUS AI is not profitable as operating profit, Profit Before Tax and Profit After Tax were negative. However, the losses are decreasing and paving the way for the company to start making profits.
ABOUT TEMPUS AI, INC.
TEMPUS AI is a medical technology company that uses artificial intelligence in healthcare by providing diagnostic and clinical trial support services.Â
